Long-Term Data on Avanafil to be Presented at the American Urological Association Annual Meeting
MOUNTAIN VIEW, Calif., May 13, 2011 /PRNewswire/ — VIVUS, Inc. (NASDAQ: VVUS) today announced that data on avanafil, its investigational drug candidate, will be featured in a late breaking oral presentation at the American Urological Association (AUA) 2011 Annual Meeting, being held May 14-19, 2011 in Washington, D.C.
Following are details about the presentation:
The oral presentation will be given at the Walter E. Washington Convention Center in Washington, D.C., on Tuesday, May 17, 2011, 1:00 PM to 3:30 PM local time during the Late-Breaking Science Forum. An oral presentation and accompanying poster will be presented by Dr. Laurence Belkoff, Chairman of the Department of Specialty Surgeries and the Division of Urology at the Philadelphia College of Osteopathic Medicine.
Presenter: Laurence H. Belkoff, DO, FACOS Belkoff, McCullough, Jones and Authors: Goldstein An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Title: Dysfunction
Avanafil is a highly selective oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of ED. Studies to date have demonstrated that avanafil has a fast onset of action, with activity demonstrated in 15 minutes or less after administration in some subjects. VIVUS expects to file the NDA for avanafil in the second quarter of 2011.
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: -------- Investor The Trout VIVUS, Inc. Relations: Group Timothy E. Morris Brian Korb Chief Financial Officer 646-378-2923 650-934-5200
SOURCE VIVUS, Inc.